The serum pharmacokinetic profile of intravenous (i.v.) tobramycin administration was characterized for a sample of nine adult patients with cystic fibrosis (CF) who were hospitalized for an acute pulmonary exacerbation. Current recommended i.v. tobramycin dosing protocols are predicted through modeling and simulation to be suboptimal. Empirical tobramycin regimens of >15 mg/kg of body weight administered i.v. once daily should be evaluated for adult patients with CF to optimize outcomes. M orbidity and mortality in adult patients with cystic fibrosis (CF) are most often attributed to acute pulmonary exacerbations (APE) due to Pseudomonas aeruginosa (1-4). Empirical therapy for management of this exacerbation consists of the combination of an antipseudomonal beta-lactam and an aminoglycoside such as tobramycin. Higher weight-based doses of tobramycin are recommended for patients with CF (10 mg/kg of body weight/day) than for patients without CF (5 to 7 mg/kg/day) (1, 5-7). Although more-intensive weight-based doses in patients with CF have been implemented by several institutions (8), there are still concerns that these tobramycin exposures may not optimize the pharmacodynamic (PD) profile of this agent (9, 10). To address these concerns, we characterized the pharmacokinetic (PK) and PD profile of once-daily intravenous (i.v.) tobramycin administration in adult patients with CF hospitalized for an APE.
attainment of convergence, Bayesian estimates for each patient were obtained using the "population of one" utility. After the Bayesian step, goodness of fit and predictive performance were assessed as previously described (12) . Embedded with the final PK model, 5,000-subject Monte Carlo simulations (MCS) were performed for administration of tobramycin at 7, 10, 15, and 20 mg/kg once daily (1-h i.v. infusion) as a single dose by use of ADAPT 5 (13) . The population simulation without the "process noise" option was utilized, and log-normal distributions of PK parameter values were selected for all simulations. Since the aminoglycoside exposure targets for efficacy and toxicity have not been described for patients with CF, we relied on targets derived from non-CF patients. For efficacy, we modeled the probability of tobramycin effect based on a previously described logistic function developed to optimize aminoglycoside therapy for nosocomial pneumonia caused by Gram-negative bacteria (14, 15) . For toxicity, we modeled the amount of time that the drug concentration remained below the limit of detection of 0.3 mg/liter (T bld ). The goal of this dosing strategy was to achieve an undetectable concentration at the end of the dosing interval. We also evaluated the probability of achieving daily areas under the concentrationtime curve (AUCs) associated with nephrotoxicity with oncedaily administration of aminoglycosides for each regimen (14) .
Nine adult patients with CF hospitalized for an APE were studied at a mean (standard deviation [SD]) of 4.1 (2.5) days following admission. The mean (SD) age was 33.0 (12.6) years, and most patients were female (n ϭ 8) and white (100%). The mean (SD) weight and height were 53.6 (6.5) kg and 164 (6.0) cm, and the mean (SD) once-daily tobramycin dose received was 7.4 (1. The model-predicted median concentration-time profile for each regimen is illustrated in Fig. 1 , and central tendency estimates and related dispersions for AUC at 24 h (AUC 24 ) and amount of time below the limit of detection are summarized in Table 1 . As illustrated in Fig. 1 , the highest concentrations are observed at the end of the 1-h infusion, but postdistribution concentrations (2 h from the start of infusion) are expected to be 20 to 40 mg/liter with regimens of 10 to 20 mg/kg once daily. The probabilities of a positive clinical effect are Ͼ80% with Ն10 mg/kg once daily against isolates for which the MIC is Յ1 mg/liter and Ն15 mg/kg against isolates for which the MIC is Յ2 mg/liter (Fig. 2) . The mean (SD) probability of effect is 71 (5.0) % with a 20-mg/kg once-daily tobramycin dose against isolates for which the MICs is 4 mg/liter. Although T bld was highly variable, the probability of concentrations below the limit of detection is 100% for all tested dosing regimens. The distributions of daily AUCs associated with all regimens were well below the daily AUCs associated with nephrotoxicity with once-daily administration of aminoglycosides (14) .
Our population model and predicted exposure profiles for tobramycin are consistent with previous publications that have evaluated this agent in patients with CF across a dosage range of 7 to 15 mg/kg (9, 10, (16) (17) (18) . These data suggest that empirical tobramycin dosing strategies that are based on 7-to 10-mg/kg regimens lead to exposures that may be optimal for cases where the MIC for the pathogen is Յ1 mg/liter. However, for bacterial pathogens for which the MIC is 2 to 4 mg/liter, which is often the case in patients with CF, tobramycin doses of 15 to 20 mg/kg/day should increase the probability of clinical response. This higher-dosing strategy should also reduce the probability for emergence of resistance at treatment initiation, when the lung bacterial burden is expected to be at its highest (19) . Although the suggested consideration of 15-to 20-mg/kg/day doses may be perceived to be high at first glance, it is important to recognize that all adult CF patients are likely to have undetectable trough concentrations, a marker of clinical safety, and the median T bld is 2.32 to 3.51 h over the 24-h dosing interval ( Table 1 ). The best evidence to date also demonstrates that the daily AUCs with the simulated 20-mg/kg/day regimen are well below the daily AUCs associated with nephrotoxicity with once-daily administration of aminoglycosides (14) . Finally and most importantly, there are data to suggest that administration of 15-to 20-mg/kg/day doses are safe and well tolerated (20, 21) . Patients with CF receive repeated courses of tobramycin during their lifetime. The auditory, vestibular, and renal safety levels of these repeated doses, high doses, and cumulative doses (632 to 7,644 mg/kg) have been documented for this population (20, 21) . Aminoglycoside-induced nephrotoxicity is reversible in Ͼ90% of the cases where the aminoglycoside is discontinued (20) (21) (22) .
In conclusion, we sought to better quantify the PK and PD of tobramycin among adults with CF hospitalized for an APE. Overall, we found that higher weight-based once-daily doses of tobramycin are likely to be necessary in adult patients with CF for pathogens for which the MIC is 2 or 4 mg/liter. Given that tobramycin MICs for P. aeruginosa are frequently Ն2 mg/liter (23), our results suggest that a reevaluation of tobramycin treatment guidelines for this patient population is needed. Use of 15-to 20-mg/ kg/day regimens for a shorter duration of 5 to 10 days could theoretically improve the probability of effect over toxicity. This suggestion for future study aligns with the recommendations of a systematic review to define optimal treatment duration in patients with CF and of thought leaders in the field of drug dose design (19, 24) . As with all simulation studies, validation of our findings is critically important given that multidrug-resistant pathogens that can necessitate the use of tobramycin monotherapy are common in patients with CF. As part of the validations, studies should attempt to delineate the tobramycin targets for efficacy and toxicity since these targets have not been described for patients with CF.
